Myopic choroidal neovascularization treated by intravitreal bevacizumab: Comparison of two different initial doses

Graefe's Archive for Clinical and Experimental Ophthalmology

Volumn 249, Issue 4, 2011, Pages 595-599

  Ruiz Moreno, Jose M ^a,b,d   Montero, Javier A ^b,c   Amat Peral, Pedro ^b  

^a UNIVERSITY OF CASTILLA LA MANCHA   (Spain)

^b Alicante   (Spain)

^c UNIVERSITY OF VALLADOLID   (Spain)

^d Facultad de Medicina   (Spain)

Author keywords

Bevacizumab; Choroidal neovascularization; High myopia; Intravitreal injection

Indexed keywords

BEVACIZUMAB;

ABSENCE OF SIDE EFFECTS; ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BEST CORRECTED VISUAL ACUITY; CENTRAL FOVEAL THICKNESS; CLINICAL ARTICLE; CLINICAL EVALUATION; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE ACTIVITY; DOSAGE SCHEDULE COMPARISON; DRUG RESPONSE; EYE DISEASE; FEMALE; FLUORESCENCE ANGIOGRAPHY; HUMAN; JUXTAFOVEAL MYOPIC SUBRETINAL NEOVASCULARIZATION; MALE; MYOPIC SUBRETINAL NEOVASCULARIZATION; OFF LABEL DRUG USE; OPTICAL COHERENCE TOMOGRAPHY; PILOT STUDY; PRIORITY JOURNAL; REPEATED DRUG DOSE; SINGLE DRUG DOSE; SUBFOVEAL MYOPIC SUBRETINAL NEOVASCULARIZATION; SUBRETINAL NEOVASCULARIZATION; SYSTEMIC DISEASE; TREATMENT OUTCOME; VISUAL ACUITY; VISUAL SYSTEM PARAMETERS;

ADULT; AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; CHOROIDAL NEOVASCULARIZATION; FEMALE; FLUORESCEIN ANGIOGRAPHY; FOLLOW-UP STUDIES; HUMANS; INTRAVITREAL INJECTIONS; MALE; MIDDLE AGED; MYOPIA, DEGENERATIVE; PILOT PROJECTS; PROSPECTIVE STUDIES; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; YOUNG ADULT;

EID: 79955608869     PISSN: 0721832X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00417-010-1599-z     Document Type: Article

References (28)

1. Cohen SY, Laroche A, Leguen Y, Soubrane G, Coscas GJ (1996) Etiology of choroidal neovascularization in young patients. Ophthalmology 103:1241-1244 (Pubitemid 26282507)
2. Ruiz-Moreno JM, Montero JA (2002) Long-term visual acuity after argon green laser photocoagulation of juxtafoveal choroidal neovascularization in highly myopic eyes. Eur J Ophthalmol 12:117-122 (Pubitemid 34587109)
3. Secretan M, Kuhn D, Soubrane G, Coscas G (1997) Long-term visual outcome of choroidal neovascularization in pathologic myopia: natural history and laser treatment. Eur J Ophthalmol 7:307-316 (Pubitemid 28042043)
4. Cekic O, Ohji M, Fujikado T, Fang XY, Hayashi A, Kusaka S, Tano Y (2000) Foveal translocation surgery and myopic subfoveal CNV membrane. Ophthalmology 107:2117
5. Uemura A, Thomas M (2000) Subretinal surgery for choroidal neovascularization in patients with high myopia. Arch Ophthalmol 118:344-350 (Pubitemid 30152374)
6. Verteporfin in Photodynamic Therapy Study Group (2001) Photodynamic therapy of subfoveal choroidal neovascularization in pathologic myopia with verteporfin. 1-year results of a randomized clinical trial - VIP report no. 1. Ophthalmology 108:841-852
7. Montero JA, Ruiz-Moreno JM (2003) Verteporfin photodynamic therapy in highly myopic subfoveal choroidal neovascularisation. Br J Ophthalmol 87:173-176 (Pubitemid 36152743)
8. Ruiz-Moreno JM, Montero JA (2003) Subretinal fibrosis after photodynamic therapy in subfoveal choroidal neovascularisation in highly myopic eyes. Br J Ophthalmol 87:856-859 (Pubitemid 36765249)
9. Degenring RF, Jonas JB (2005) Photodynamic therapy in combination with intravitreal triamcinolone for myopic choroidal neovascularization. Acta Ophthalmol Scand 83:621 (Pubitemid 41488642)
10. Marticorena J, Gomez-Ulla F, Fernandez M, Pazos B, Rodriguez-Cid MJ, Sanchez-Salorio M (2006) Combined photodynamic therapy and intravitreal triamcinolone acetonide for the treatment of myopic subfoveal choroidal neovascularization. Am J Ophthalmol 142:335-337 (Pubitemid 44107278)
11. Montero JA, Ruiz-Moreno JM (2007) Combined photodynamic therapy and intravitreal triamcinolone injection for the treatment of choroidal neovascularisation secondary to pathological myopia: a pilot study. Br J Ophthalmol 91:131-133 (Pubitemid 46202852)
12. Silva RM, Ruiz-Moreno JM, Nascimento J, Carneiro A, Rosa P, Barbosa A et al (2008) Short-term efficacy and safety of intravitreal ranibizumab for myopic choroidal neovascularization. Retina 28:1117-1123
13. Sakaguchi H, Ikuno Y, Gomi F, Kamei M, Sawa M, Tsujikawa M, Oshima Y, Kusaka S, Tano Y (2007) Intravitreal injection of bevacizumab for choroidal neovascularisation associated with pathological myopia. Br J Ophthalmol 91:161-165 (Pubitemid 46202863)
14. Tewari A, Dhalla MS, Apte RS (2006) Intravitreal bevacizumab for treatment of choroidal neovascularization in pathologic myopia. Retina 26:1093-1094 (Pubitemid 44973239)
15. Yamamoto I, Rogers AH, Reichel E, Yates PA, Duker JS (2007) Intravitreal bevacizumab (Avastin) as treatment for subfoveal choroidal neovascularisation secondary to pathological myopia. Br J Ophthalmol 91:157-160 (Pubitemid 46202862)
16. Ruiz-Moreno JM, Montero JA, Gomez-Ulla F, Ares S (2009) Intravitreal bevacizumab to treat subfoveal choroidal neovascularisation in highly myopic eyes: 1-year outcome. Br J Ophthalmol 93:448-451
17. Mandal S, Venkatesh P, Sampangi R, Garg S (2007) Intravitreal bevacizumab (Avastin) as primary treatment for myopic choroidal neovascularization. Eur J Ophthalmol 17:620-626 (Pubitemid 47605773)
18. Hernandez-Rojas ML, Quiroz-Mercado H, Dalma-Weiszhausz J, Fromow-Guerra J, Amaya-Espinosa A, Solis-Vivanco A, Reyna- Castelan E, Abraham-Marin M, Martinez-Castellanos MA, Aiello LP (2007) Short-term effects of intravitreal bevacizumab for subfoveal choroidal neovascularization in pathologic myopia. Retina 27:707-712 (Pubitemid 47051766)
19. Chan WM, Lai TY, Liu DT, Lam DS (2007) Intravitreal bevacizumab (Avastin) for myopic choroidal neovascularization: six-month results of a prospective pilot study. Ophthalmology 114:2190-2196
20. Ruiz-Moreno JM, Gomez-Ulla F, Montero JA, Ares S, Lopez-Lopez F, Rodriguez M, Fernandez M (2009) Intravitreous bevacizumab to treat subfoveal choroidal neovascularization in highly myopic eyes: short-term results. Eye 23:334-338
21. Chan WM, Lai TY, Liu DT, Lam DS (2009) Intravitreal bevacizumab (Avastin) for myopic choroidal neovascularisation: 1-year results of a prospective pilot study. Br J Ophthalmol 93:150-154
22. Gharbiya M, Allievi F, Mazzeo L, Gabrieli CB (2009) Intravitreal bevacizumab treatment for choroidal neovascularization in pathologic myopia: 12-month results. Am J Ophthalmol 147(84-93):e81
23. Ikuno Y, Sayanagi K, Soga K, Sawa M, Tsujikawa M, Gomi F, Tano Y (2009) Intravitreal bevacizumab for choroidal neovascularization attributable to pathological myopia: one-year results. Am J Ophthalmol 147(94-100):e101
24. Wu PC, Chen YJ (2009) Intravitreal injection of bevacizumab for myopic choroidal neovascularization: 1-year follow-up. Eye 23 (11):2042-2045
25. Arias L, Caminal JM, Casas L, Masuet C, Badia MB, Rubio M, Pujol O, Arruga J (2008) A study comparing two protocols of treatment with intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Br J Ophthalmol 92:1636-1641
26. Garcia-Layana A, Salinas-Alaman A, Maldonado MJ, Sainz-Gomez C, Fernandez-Hortelano A (2006) Optical coherence tomography to monitor photodynamic therapy in pathological myopia. Br J Ophthalmol 90:555-558
27. Laud K, Spaide RF, Freund KB, Slakter J, Klancnik JM Jr (2006) Treatment of choroidal neovascularization in pathologic myopia with intravitreal bevacizumab. Retina 26:960-963 (Pubitemid 44547453)
28. Nguyen QD, Shah S, Tatlipinar S, Do DV, Anden EV, Campochiaro PA (2005) Bevacizumab suppresses choroidal neovascularisation caused by pathological myopia. Br J Ophthalmol 89:1368-1370 (Pubitemid 41638883)